Astellas Pharma Inc.
ALPMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,544,403 | $505,794,000 | $459,294,000 | $517,408,000 |
| % Growth | -99.3% | 10.1% | -11.2% | – |
| Cost of Goods Sold | $934,584 | $94,829,000 | $76,858,000 | $98,523,000 |
| Gross Profit | $2,609,820 | $410,965,000 | $382,436,000 | $418,885,000 |
| % Margin | 73.6% | 81.3% | 83.3% | 81% |
| R&D Expenses | $483,955 | $71,698,000 | $76,229,000 | $79,092,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,398,218 | $196,997,000 | $211,316,000 | $225,305,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $47,623,000 | $31,371,000 | $230,679,000 |
| Operating Expenses | $1,882,173 | $316,318,000 | $318,916,000 | $535,076,000 |
| Operating Income | $727,646 | $94,647,000 | $63,520,000 | -$116,191,000 |
| % Margin | 20.5% | 18.7% | 13.8% | -22.5% |
| Other Income/Exp. Net | -$23,322 | -$4,231,000 | -$2,966,000 | -$2,168,000 |
| Pre-Tax Income | $704,324 | $90,416,000 | $60,554,000 | -$118,359,000 |
| Tax Expense | $168,845 | $21,994,000 | -$14,342,000 | -$20,699,000 |
| Net Income | $535,480 | $68,422,000 | $74,896,000 | -$97,660,000 |
| % Margin | 15.1% | 13.5% | 16.3% | -18.9% |
| EPS | 0.3 | 38.22 | 41.83 | -54.57 |
| % Growth | -99.2% | -8.6% | 176.7% | – |
| EPS Diluted | 0.3 | 38.11 | 41.19 | -54.57 |
| Weighted Avg Shares Out | 1,791,152 | 1,795,382 | 1,818,098 | 1,789,760 |
| Weighted Avg Shares Out Dil | 1,797,732 | 1,795,382 | 1,818,213 | 1,789,760 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,548 | $0 | $0 | $0 |
| Interest Expense | $18,205 | $4,231,000 | $2,967,000 | $2,167,000 |
| Depreciation & Amortization | $319,707 | $47,804,000 | $47,683,000 | $51,164,000 |
| EBITDA | $1,042,162 | $151,845,000 | $101,785,000 | $126,058,000 |
| % Margin | 29.4% | 30% | 22.2% | 24.4% |